6 Undervalued Biotechnology & Medical Research Stocks for Friday, July 12
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Friday, July 12 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Commentary & Analysis
5 Undervalued Biotechnology & Medical Research Stocks for Wednesday, May 29
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Wednesday, May 29 based on AAII’s Stock Grades.Jack Gilleland
7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, March 19
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Tuesday, March 19 based on AAII’s Stock Grades.Eunice Kim
5 Undervalued Biotechnology & Medical Research Stocks for Friday, February 02
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Friday, February 02 based on AAII’s Stock Grades.Eunice Kim
6 Undervalued Biotechnology & Medical Research Stocks for Tuesday, January 02
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Tuesday, January 02 based on AAII’s Stock Grades.Jenna Brashear
Financial Summary
| Share Statistics | XBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.9 | $286.3 | 5% |
|
| Shares Out (Mil) | 2.3 | 54.2 | 8% |
|
| Institutional Ownership | 41.0% | 92.8% | 17% |
|
| Float (Mil) | 1.9 | 39.7 | 5% |
|
| Beta | 2.15 | 0.94 | 94% |
|
| Avg Daily Volume (000s) | 94 | 534 | 34% |
|
| Price Change (52-week) |
20.3% | 58.7% | 62% |
|
| Growth | XBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 49.6% | 13.6% | 96% |
|
| Net Income (5yr) | 24.4% | (10.1%) | 79% |
|
| EPS (5yr) | 37.9% | 16.0% | 87 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (11.0%) | (15.6%) | 58% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $37 | 4% |
|
| Net Income (TTM) (Mil) | ($3) | ($43) | 36% |
|
| EPS (TTM) | ($1.192) | ($1.400) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($31) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1 | $160 | 4% |
|
| Valuation | XBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.31 | 2.77 | 33% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | XBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.2% | 96% |
|
| Net Margin | (75.9%) | (75.9%) | 9% |
|
| ROA | (40.2%) | (47.3%) | 14% |
|
| ROE | (47.0%) | (55.0%) | 16% |
|
| Liabilities to Assets | 12.8% | 29.6% | 8% |
|
| F-Score | 5 | 2 | 50% |
|
Xenetic Biosciences, Inc. did not pass any screens on 8/20/2026.
